Table 4. Variables associated with CDI after allogeneic HCT (N=385; p≤0.20)a.
| Variable | CDI N (%) |
No CDI N (%) |
OR (95% CI) | p-value |
|---|---|---|---|---|
| Risk Factors | ||||
| Comorbidities | ||||
| Other cardiovascular disease | 35 (29) | 48 (18) | 1.9 (1.1 – 3.1) | 0.015 |
| Diabetes not requiring insulin | 9 (8) | 8 (3) | 2.6 (1.0 – 6.9) | 0.047 |
| No comorbid disease | 37 (31) | 123 (46) | 0.5 (0.3 – 0.8) | 0.004 |
| Pre-transplant medications | ||||
| Dexamethasone (high dose) | 24 (20) | 33 (13) | 1.8 (1.0 – 3.1) | 0.053 |
| ATGAM | 7 (6) | 26 (10) | 0.6 (0.2 – 1.4) | 0.20 |
| Other immunomodulator | 32 (27) | 53 (20) | 1.5 (0.9 – 2.4) | 0.14 |
| Fludarabine | 41 (34) | 115 (43) | 0.7 (0.4 – 1.1) | 0.09 |
| Busulfan | 67 (56) | 171 (65) | 0.7 (0.4 – 1.1) | 0.10 |
| Campath | 0 (0) | 7 (3) | Undef | 0.10c |
| Myeloablative conditioning | 33 (61) | 55 (38) | 2.6 (1.4 – 4.9) | 0.003 |
|
Severity of illness in 30 days before
index date |
||||
| Symptomatic UTI | 7 (6) | 5 (2) | 3.2 (1.0 – 10.4) | 0.055c |
| Graft versus host disease (any) | 28 (23) | 31 (12) | 2.3 (1.3 – 4.0) | 0.003 |
| Outcomes | ||||
| Pneumonia | 7 (6) | 8 (3) | 2.0 (0.7 – 5.6) | 0.19 |
| Viremia | 14 (12) | 16 (6) | 2.1 (1.0 – 4.4) | 0.056 |
| Respiratory tract infection | 0 (0) | 7 (3) | Undef | 0.10c |
| Graft versus host disease (any) | 48 (40) | 71 (27) | 1.8 (1.2 – 2.9) | 0.009 |
Potential risk factors and outcomes with p>0.20 not included in the table: Age, sex, race, coronary artery disease, congestive heart failure, peripheral vascular disease, COPD, asthma, other pulmonary disease, GERD, cirrhosis, other GI disease, chronic renal insufficiency, end stage renal disease, hemodialysis, peritoneal dialysis, splenectomy, diabetes requiring insuling, autoimmune disease, HIV, HCV, HBV, other disease, unmatched HCT donor, unrelated HCT donor, status of malignancy; other pre-transplant medications, ICU admission, mechanical ventilation, renal failure, dialysis, bloodstream infection, pneumonia, febrile neutropenia, viremia, or respiratory tract infection in 30 days before index date; ICU admission, mechanical ventilation, renal failure, dialysis, bloodstream infection, symptomatic UTI, febrile neutropenia, or respiratory tract infection in 30 days after index date.
Fisher’s exact test.